Skip to content

Advertisement

  • Research article
  • Open Access

Bioinformatics analysis of microarray data to reveal the pathogenesis of diffuse intrinsic pontine glioma

†Contributed equally
Biological Research201851:26

https://doi.org/10.1186/s40659-018-0175-6

©  The Author(s) 2018

  • Received: 18 December 2017
  • Accepted: 12 August 2018
  • Published:

Abstract

Background

Diffuse intrinsic pontine glioma (DIPG) is the main cause of pediatric brain tumor death. This study was designed to identify key genes associated with DIPG.

Methods

The gene expression profile GSE50021, which consisted of 35 pediatric DIPG samples and 10 normal brain samples, was downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) were identified by limma package. Functional and pathway enrichment analyses were performed by the DAVID tool. Protein–protein interaction (PPI) network, and transcription factor (TF)–microRNA (miRNA)–target gene network were constructed using Cytoscape. Moreover, the expression levels of several genes were validated in human glioma cell line U251 and normal glia HEB cells through real-time polymerase chain reaction (PCR).

Results

A total of 378 DEGs were screened (74 up-regulated and 304 down-regulated genes). In the PPI network, GRM1, HTR2A, GRM7 and GRM2 had higher degrees. Besides, GRM1 and HTR2A were significantly enriched in the neuroactive ligand–receptor interaction pathway, and calcium signaling pathway. In addition, TFAP2C was a significant down-regulated functional gene and hsa-miR-26b-5p had a higher degree in the TF-miRNA-target gene network. PCR analysis revealed that GRM7 and HTR2A were significantly downregulated while TFAP2C was upregulated in U251 cells compared with that in HEB cells (p < 0.001). GRM2 was not detected in cells.

Conclusions

GRM1 and HTR2A might function in DIPG through the neuroactive ligand–receptor interaction pathway and the calcium signaling pathway. Furthermore, the TFAP2C and hsa-miR-26b-5p might play important roles in the development and progression mechanisms of DIPG.

Keywords

  • Diffuse intrinsic pontine glioma
  • Differentially-expressed genes
  • Neuroactive ligand–receptor interaction
  • Protein–protein interaction network
  • Transcription factor–microRNA–target gene network

Background

Diffuse intrinsic pontine glioma (DIPG) is the most common brain tumor in childhood [1]. The mortality of DIPG goes up with no available treatment, almost 100% fatality [2]. Although DIPG can be treated by radiotherapy and chemotherapy, the average survival time has remained only 9 months and 5-year survival time is less than 1% [3]. There were no obviously advantages of radiation and chemotherapy [4]. The development of therapies for DIPG was greatly hampered because of lack of therapeutic benefits and molecular studies [5]. Therefore, a better understanding of the molecular mechanisms underlying DIPG is helpful to develop new therapies for this disease.

In the past few years, DIPG cell cultures and orthotopic xenograft models have been established [6, 7]. Previous study showed that grade of gliomas in human brain was related to the R-Ras expression and phosphorylation, indicating the EphB2/R-Ras signaling pathway as a potential target associated with cell adsorption, growth and invasion [8]. Holland et al. [9] found that activation of Ras and Akt in neural progenitor cells can induce glioma in mice, and the Ras and Akt proteins play important roles in the pathogenesis of gliomas. These studies suggest that a single gene or the interaction between more genes involved in the promotion of disease occurrence and development. In recent years, the advantage of gene chip technology and bioinformatics analysis is obviously observed, which is applied to analyze the molecular mechanism of DIPG [10]. Deng et al. [10] showed cholecystokinin (CCK) and gastrin (GAST) associated with the G-protein coupled receptor (GPCR) signaling pathway, and 5-hydroxytryptamine (serotonin) receptor 7 (HTR7) involved in the neuroactive ligand–receptor interaction might play critical roles in DIPG. Despite a number of researches have investigated the molecular basis of DIPG, the molecular mechanisms of the disease remain not fully understood.

In the study of Buczkowicz et al. [2], the gene expression profile GSE50021 was utilized only for surveying what urged DIPGs by whole-genome sequencing. In the study of Deng et al. [10], GSE50021 was analyzed and revealed a potential key molecular mechanisms in DIPG by microarray analysis and bioinformatics analysis. Recently, Xi et al. [11] used a novel method for extracting DEGs from GSE50021 in combination with GSE50022 that included DNA methylation. However, given the complicated molecular mechanisms of DIPG, it is necessary to fully utilize GSE50021 profile to identify more potential genes and pathways related to DIPG. In this study, differentially-expressed genes (DEGs) were indentified from GSE50021 dataset. Subsequently, enrichment analysis, protein–protein interaction (PPI) network, module analyses, and microRNAs (miRNAs)–transcription factors (TFs)–target gene regulatory network analysis were successively performed to identify the key genes implicated in the pathogenesis of DIPG. Importantly, several key genes were validated through real-time polymerase chain reaction (PCR).

Methods

Microarray data

The gene expression profile GSE50021 was downloaded from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) database [12], which was based on the platform of GPL13938 Illumina HumanHT-12 WG-DASL V4.0 expression beadchip. This dataset, including 35 DIPG samples and 10 normal brain samples, was deposited by Buczkowicz et al. [2].

Data preprocessing and DEGs screening

Using robust multi-array average (RAM) [13] method of Affy package (http://www.bioconductor.org/packages/release/bioc/html/affy.html) in R language, the raw data were preprocessed, including background correction, normalization and expression calculation. The platform annotation file was used to annotate the probes, and the probes without corresponding gene symbols were removed. For different probes mapped to the same gene, the average value of the probes was taken as the final gene expression value. DEGs were identified by the classical Bayes method in Limma package [14] (http://www.bioconductor.org/packages/2.9/bioc/html/limma.html). The genes with adjusted p-value < 0.05 were chosen as DEGs.

Functional and pathway enrichment analyses

Gene Ontology (GO) (http://www.geneontology.org) analysis [15], including biological process (BP), molecular function (MF), and cellular component (CC), is used for functional study of single gene or large-scale genome. The Kyoto Encyclopedia of Genes and Genomes (KEGG, http://www.genome.ad.jp/kegg/) [16, 17] is the major recognized pathway-related database, which takes into account not only each KEGG pathway itself, but also its related pathways [17]. The DAVID online tool (https://david-d.ncifcrf.gov/) [18] was used to perform GO functional and KEGG pathway enrichment analysis for the DEGs. The p-value of < 0.05 and gene count ≥ 2 were chosen as the significant thresholds. In order to directly observe the functions of DEGs, the ClueGO plug-in [19, 20] http://apps.cytoscape.org/apps/ClueGO) of Cytoscape [21] was applied to visualize the results of enrichment analysis in figures, and p-value of < 0.05 was chosen as the significant threshold.

PPI network and module analyses

The Search Tool for the Retrieval of Interacting Genes (STRING) [22] (http://www.string-db.org/) is an online database providing experimental and predicted PPI information. In this study, the STRING database [22] was used to analyze the PPIs among the proteins encoded by the DEGs with a combined score of > 0.4, then the PPI networks for the up-regulated and the down-regulated genes were separately visualized by Cytoscape software (http://www.cytoscape.org/) [21]. The CytoNCA plug-in [23] (http://apps.cytoscape.org/apps/cytonca) in Cytoscape software was used to analyze the topological property of the network, acquiring the important nodes in the PPI network combined with the degree of each node.

In addition, module analysis was performed for the PPI networks using the MCODE plug-in (http://apps.cytoscape.org/apps/mcode) [24] in Cytoscape software. An adjusted p < 0.01 was chosen as the significance threshold. In addition, the nodes in the significant modules were performed GO functional and KEGG pathway enrichment analyses using DAVID online tool [18].

Construction of TF-miRNA-target gene regulatory network

At the post-transcription stage, miRNAs regulate gene expression [25]. Whereas, TFs can promote or repress transcription at a pre-transcription stage [26]. TF-miRNA-target gene acts as a tumor suppressor network, triggering a comprehensive change in genetic programs involving cell proliferation, apoptosis and cancer invasion in cancer [27]. The miRNAs associated with DIPG and their target genes were searched using miRWalk2.0 database [28] (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/). Through comparing target genes with the DEGs, miRNA-DEG pairs were obtained. Then, miRNA-DEG regulatory network was visualized by Cytoscape software [21].

The iRegulon plug-in [29] (http://apps.cytoscape.org/apps/iRegulon) in Cytoscape software, which included the TF-target pairs of multiple human databases such as Transfac (http://www.gene-regulation.com/pub/databases.html) [30], and Encode (https://www.encodeproject.org/) [31, 32], was used to predict the TF-target pairs in the miRNA-DEG regulatory network, A normalized enrichment score (NES) > 3 was chosen as the significant threshold for screening TF-target pairs. Additionally, the TF-miRNA-target regulatory network was visualized using Cytoscape software [21].

Real-time PCR verification of the expression of key genes

Human glioma cell line U251, a common used DIPG cell line [33], was purchased from cell bank of Chinese Academy of Sciences (Shanghai, China) and normal glia HEB cells [33] were purchased from GuangZhou Jennio Biotech Co., Ltd, Guangdong, China. All cells were grown in Dulbecco’s modified eagle medium supplemented with 10% fetal bovine serum and 1% antibiotics (penicillin and streptomycin) at 37  °C in an atmosphere of 10% CO2.

Briefly, total RNAs were isolated from 5 × 106 to 10 × 106 cell samples using a TRIzol reagent (Invitrogen, CA, USA). RNA concentration and quality were determined using a TECAN infinite M100 PRO Biotek microplate reader (TECAN, CA, USA). Total RNA (0.5 μg) was used for cDNA synthesis using the PrimeScript RT Master Mix (RR036A; Takara, Dalian, China). PCR was performed using the SYBR GREEN kit (4367659; Thermo, USA) in Viia7 Real-Time PCR System (Applied Biosystems, USA). The primers used in this study are listed in Table 1.
Table 1

The primers used in real time PCR

Primer name

Sequences (5′-3′)

GRM2-hF

GCTCCACTCCGATTCTCTCC

GRM2-hR

GAAGCAGCGAAGGCAAAGAG

GRM7-hF

GACACTTACGCGCTCGAACA

GRM7-hR

TCATCACTTAGCTCGGGTGC

HTR2A-hF

CTGGTCTGCTTTACTGACAGCC

HTR2A-hR

AGAGCACGTCCAGGTAAATCC

GAPDH-hF

TGACAACTTTGGTATCGTGGAAGG

GAPDH-hR

AGGCAGGGATGATGTTCTGGAGAG

Statistical analysis

Data are presented as mean ± standard deviation. Statistical analysis was performed using SPSS 22.0 (IBM, Armonk, NY, USA). Differences in gene expression levels between groups were analyzed by one-way analysis of variance. The p < 0.05 was considered significant.

Results

DEGs screening

As shown in Fig. 1, the medians located at the same level after performing data normalization, which indicated a perfect effect. Based on adjusted p-value < 0.05, 378 DEGs were identified, which included 74 up-regulated and 304 down-regulated genes.
Fig. 1
Fig. 1

The box figures before and after normalization. Red and white separately represent the diffuse intrinsic pontine glioma (DIPG) samples and the normal samples

Functional and pathway enrichment analyses

According to the p-values (ascending sort), the top five enriched terms are exhibited in Fig. 2. The up-regulated genes were significantly enriched in the modification-dependent macromolecule catabolic process (BP, p = 0.044), nucleotide binding (MF, p = 0.007), cytosolic part (CC, p = 0.044), and antigen processing and presentation (pathway, p = 0.01) (Fig. 2a). While the down-regulated genes were significantly associated with neurological system process (BP, p = 2.33E−08), ion channel activity (MF, p = 6.64E−09), plasma membrane part (CC, p = 1.48E−08), neuroactive ligand–receptor interaction (pathway, p = 1.57E−08) and calcium signaling pathway (pathway, p = 4.18E−06) (Fig. 2b).
Fig. 2
Fig. 2

The top five GO terms and KEGG pathways enriched separately for the up-regulated genes (a) and the down-regulated (b). MF molecular function, BP biological processes, CC cellular components, KEGG Kyoto Encyclopedia of Genes and Genomes, GO gene ontology; The horizontal axis represents the count of enriched DEGs. The vertical axis represents the enriched GO terms and KEGG pathways

Furthermore, the crosslinking enrichment of GO-BP terms and KEGG pathways are shown in Fig. 3. The more down-regulated genes were related to the disease, and the main pathway was neuroactive ligand–receptor interaction (Fig. 3).
Fig. 3
Fig. 3

The crosslinking enrichment of GO-BP terms and KEGG pathways enriched separately for the up-regulated genes (a) and the down-regulated (b). The nodes with different color represent different GO-BP or KEGG pathways. GO gene ontology, BP biological processes, KEGG Kyoto Encyclopedia of Genes and Genomes

PPI network and module analyses

Based on the STRING database, the PPI network for the DEGs (including 231 nodes and 490 edges) was constructed (Fig. 4). Up-regulated gene with higher node degree was glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Down-regulated genes had higher degrees were as follows: nerve peptide Y (NPY), 5-hydroxytryptamine receptor 2A (HTR2A), metabotropic glutamate receptor 1 (GRM1), adenylate cyclase 2 (ADCY2), GRM2, GRM7 and so on. The nodes with degree ≥ 10 are listed in Table 2.
Fig. 4
Fig. 4

Protein–protein interaction network constructed for the DEGs. The red circle and the green rhombus represent up-regulated genes and down-regulated genes, respectively. The nodes in Module 1, Module 2 and Module 3 separately were marked by blue, purple and yellow edges. DEGs differentially-expressed genes

Table 2

The differentially-expressed genes (DEGs) with a degree > 10 in the protein–protein interaction (PPI) network

Gene

Description

Degree

Gene

Description

Degree

Gene

Description

Degree

GAPDH

Up

27

CAMK2B

Down

16

HTR2A

Down

12

MAPK1

Down

23

AVP

Down

16

TAC3

Down

12

NPY

Down

22

TNF

Down

16

VIP

Down

11

DLG2

Down

22

CCK

Down

15

ADRA1A

Down

11

NOS3

Down

20

GRIN1

Down

15

CHRM1

Down

11

GRM1

Down

20

GRM7

Down

15

ADRA1B

Down

10

GRP

Down

16

ADCY2

Down

14

P2RY6

Down

10

PDYN

Down

16

GRM2

Down

14

SLC17A7

Down

10

Additionally, three significant modules, including module 1 (19 nodes and 95 edges), module 2 (5 nodes and 10 edges) and module 3 (9 nodes and 15 edges), were acquired by MCODE plug-in (Fig. 4).

Furthermore, 10 KEGG pathways were significantly enriched by module 1, including neuroactive ligand–receptor interaction (p = 7.94E−12), calcium signaling (p = 1.83E−05), glutamatergic synapse (p = 1.39E−03). Meanwhile, the nodes in module 3 were significantly enriched in four KEGG pathways, including cocaine addiction (p = 2.37E−06), nicotine addiction (p = 6.74E−04), cAMP signaling pathway (p = 1.56E−02) and glutamatergic synapse (p = 4.86E−02) (Table 3). However, no pathways were enriched for the nodes in module 2.
Table 3

The enriched pathways for the nodes in module 1 and 3

Pathway name

Count

p-value

Genes

Module 1

 hsa04080:neuroactive ligand–receptor interaction

11

7.94E−12

P2RY6, GRM2, OPRL1, P2RY14, CHRM1, GRM7, ADRA2A, ADRA1B, ADRA1A, GRM1, HTR2A

 hsa04020:calcium signaling pathway

6

1.83E−05

ADCY2, CHRM1, ADRA1B, ADRA1A, GRM1, HTR2A

 hsa04724:glutamatergic synapse

4

1.39E−03

ADCY2, GRM2, GRM7, GRM1

 hsa04022:cGMP-PKG signaling pathway

4

4.08E−03

ADCY2, ADRA2A, ADRA1B, ADRA1A

 hsa04970:salivary secretion

3

1.26E−02

ADCY2, ADRA1B, ADRA1A

 hsa04540:gap junction

3

1.32E−02

ADCY2, GRM1, HTR2A

 hsa04270:vascular smooth muscle contraction

3

2.34E−02

ADCY2, ADRA1B, ADRA1A

 hsa04261:adrenergic signaling in cardiomyocytes

3

3.42E−02

ADCY2, ADRA1B, ADRA1A

Module 3

 hsa04724:glutamatergic synapse

5

2.37E−06

SLC17A7, DLGAP1, GRIN1, GRIN3A, SHANK2

 hsa05033:nicotine addiction

3

6.74E−04

SLC17A7, GRIN1, GRIN3A

 hsa04024:cAMP signaling pathway

3

1.56E−02

GRIN1, GHRL, GRIN3A

 hsa05030:cocaine addiction

2

4.86E−02

GRIN1, GRIN3A

TF-miRNA-target regulatory network analysis

A total of 36 miRNAs associated with DIPG were identified from miRWalk2.0, and only 27 miRNAs remained after removing the repeats and the miRNAs in mice. The target genes of the remaining miRNAs were compared with the DEGs and a total of 141 miRNA-DEG pairs were obtained. The miRNA-DEG regulatory network was visualized by Cytoscape software, consisting of 136 nodes and 368 edges (Fig. 5). Based on the iRegulon plug-in, a total of nine TFs were identified from the miRNA-DEG regulatory network. Then, the TF-miRNA-target regulatory network was constructed and the nodes with top 10 degrees are listed in Table 4. The TFAP2C was a significant down-regulated functional gene, while the hsa-miR-26b-5p had a higher degree in the TF-miRNA-target regulatory network.
Fig. 5
Fig. 5

The miRNA-TF-target regulatory network. The red circle and the green rhombus represent up-regulated genes and down-regulated genes, respectively. The blue triangle represents miRNA, and yellow hexagon indicates TFs. T shape represents the miRNA-target relationship, and arrow represents TF-target relationship. DEGs differentially-expressed genes, TFs transcription factors, miRNAs microRNAs

Table 4

The differentially-expressed genes (DEGs) with a degree > 10 in the transcription factors–microRNAs–target regulatory network

Gene

Description

Degree

Gene

Description

Degree

REST

TF

71

hsa-miR-218-5p

miRNA

15

hsa-miR-26b-5p

miRNA

41

SPIB

TF

12

TFAP2C

TF/down

39

EP300

TF

12

TEAD4

TF

36

hsa-miR-26a-5p

miRNA

11

DUS3L

TF

24

ZNF143

TF

10

ARX

TF

15

UBR4

Up

10

Real-time PCR verification of the expression of key genes

Expression levels of GRM2, GRM7, HTR2A and TFAP2C were determined using real-time PCR. As shown in Fig. 6, GRM7 and HTR2A were significantly downregulated while TFAP2C was significantly upregulated in U251 cells compared with that in HEB cells (p < 0.001). GRM2 was not detected in cells, which may be due to its expression level being too low in them or the difference between tissue and cell samples.
Fig. 6
Fig. 6

The gene expression levels of GRM7, HTR2A and TFAP2C detected by real-time polymerase chain reaction. ***p < 0.001 compared with control

Discussion

In order to identify potential genes and related pathways of DIPG, a further analysis based on bioinformatics method was performed on the GSE50021 profile. Deng et al. [10] also used GSE50021 profile to analyze candidate genes and associated pathways, and identified 679 DEGs (454 up-regulated and 225 down-regulated genes) but the results had both similarities and dissimilarities on the number and function of DEGs. In the present study, 378 DEGs were identified, including 74 up-regulated genes and 304 down-regulated genes. The difference on the number of DEGs is due to the different thresholds of DEGs screening. In the study of Deng et al. [10], genes with p-value of < 0.01 and |log2fold change (FC)| > 2.0 were selected as DEGs for further study, while our study used adjusted p-value < 0.05 as threshold. Based on the module analysis, the down-regulated genes were significantly enriched in different GO terms and pathways, for instance, the GRM1 and HTR2A were associated with neuroactive ligand–receptor interaction and calcium signaling pathway, while the ADCY2 was associated with calcium signaling pathway, in addition, NPY with higher degree in PPI network. TF-miRNA-target gene network showed that TFAP2C was a significantly down-regulated functional gene and the hsa-miR-26b-5p had a higher degree.

GRM1, GRM2 and GRM7 had higher degrees in module 1, which were enriched with neuroactive ligand–receptor interaction, calcium signaling pathway and glutamatergic synapse in KEGG pathways in this study. Chen et al. [34] demonstrated that neuroactive ligand–receptor interactions are mainly associated with DIPG. Calcium is an essential signal transduction element that regulate numerous eukaryotic cellular functions including cell cycle progression [35]. Deregulation of the calcium signalling is linked to each of the ‘cancer hallmarks’ [36]. Additionally, the expression of glutamatergic system is implicated in tumour biology [37]. Given the role of these pathways in cancers, we speculated that GRM1, GRM2 and GRM7 may be associated with DIPG progression by involving in these pathways.

GRM1, GRM2 and GRM7 belong to the glutamate receptor family, which included ionotropic glutamate receptors (iGluR) and metabotropic glutamate receptors (mGluR) [38]. The mGluRs are further divided into three groups, among which, GRM1 is owned by group I, while GRM2 and GRM7 belong to group II and III respectively [39]. Emerging evidence has suggested a role for glutamate and its receptors in the biology of cancer. Glutamate receptor antagonists could limit tumor growth [40]. Blocking expression of selected GluR subunits inhibits proliferation of cancer cells in vitro [41]. Importantly, it has been demonstrated that glutamate receptor subunits are expressed in a variety of tumors, including glioma [42]. Previous studies reported that the aberrant expression of GRM1 induced spontaneous melanoma development in vivo [43, 44]. Brocke et al. [45] demonstrated that tumor growth may be suppressed via interfering with glutamate signaling, and suggested that glutamate receptor modulators may be an adjunctive treatment for central nervous system tumors. The study has shown that the GRM2 had huge potential for treating psychiatric and neurological diseases throughout the mammalian central nervous system, and that have been proposed as major targets for the development of drugs for human psychiatric and neurological diseases [46]. Recently, Ma et al. [47] reported that GRM2 was downregulated in glioma cells, and was regulated by eight transcription factors. In our study, GRM2 had higher degree in the PPI network. Previous study has reported that hubs that are “highly connected” in a PPI network tend to correspond to essential genes, which is called the “centrality–lethality rule” [48]. All these results may suggest the essential role of GRM2 in glioma. Furthermore, De et al. [49] revealed that GRM7 was associated with mood disorders, suicide, and treatment response. GRM7 has been reported to be hypermethylated in breast cancer cells [50]. Specially, the expression level of GRM7 was validated in human glioma cell line U251. Taken together, these suggested that the GRM1, GRM2 and GRM7 might function in DIPG.

In this study, HTR2A had a higher degree and was strongly related with neuroactive ligand–receptor interactions. Besides, it was demonstrated to be down-regulated in U251 cells. Li et al. [51] have demonstrated that HTR2A are related with low-grade and high-grade gliomas via neuroactive ligand–receptor interactions. Thus, the present results suggested that HTR2A might play an important role in gliomas via neuroactive ligand–receptor interactions, which was consistent with previous findings. Besides, HTR2A was also enriched in calcium signaling pathway, meanwhile, ADCY2 was significantly related with the calcium signaling pathway as well. Being consistent with these results, Deng et al. [10] demonstrate that ADCY2 plays a role by the calcium signaling pathway in DIPG tumorigenesis. Hall et al. [52] showed that NPY-immunopositive played an important role in modulating cortical excitability of interneurons. NPY had a higher degree in the PPI network, suggesting that NPY might function in CNS.

It has been well known that TFs promote or repress transcription at a pre-transcription stage [26], while miRNA plays an important regulatory roles at the post-transcriptional level [25]. Many previous studies have investigated the pathogenesis of DIPG from transcriptional level using glioma cell line U251 [53–55]. In the present study, unlike the other studies using GSE50021 for analysis, we performed miRNA-TF-target gene regulatory network analysis in order to predict the TFs and miRNAs that may play roles in DIPG. TFAP2C was identified as candidate TF, which was a significantly down-regulated functional gene. However, result of PCR analysis showed that TFAP2C was upregulated in human glioma cell line U251, which was inconsistent with the prediction result. The contradiction may be due to the heterogeneity between tissue samples and cell samples. Further experiment is needed to detect the expression level of TFAP2C in DIPG. Study has suggested that TFAP2C promotes lung tumorigenesis by up-regulation of TGFBR1 and consequent activation of PAK1 signaling [56]. Another study showed that through regulation of RET, the expression of TFAP2C decreased in luminal breast cancer. Besides, EGFR and HER2 were regulated by TFAP2C in breast cancer [57]. Therefore, TFAP2C may play a role in cancer. The hsa-miR-26b-5p had a higher degree in the TF-miRNA-target regulatory network, which may be related to DIPG. The research indicated that proliferation and apoptosis in lung cancer cells were inhibited via a miR-26b-5p-EZH2-mediated approach [58]. Although the roles of TFAP2C and hsa-miR-26b-5p in DIPG have not been discussed, we inferred that TFAP2C and hsa-miR-26b-5p may play roles in DIPG tumorigenesis. Further genetic studies are required to verify this hypothesis.

Specially, the present study used real-time PCR to verify the expression of key genes GRM2, GRM7, HTR2A and TFAP2C through human glioma cell line U251. GRM7 and HTR2A were significantly downregulated in U251 cells compared with that in HEB cells, which was in accordance with the analysis results. GRM2 was not detected in cells, which may be due to its expression level being too low in U251 cells or the difference between tissue and cell samples. TFAP2C was upregulated in human glioma cell line U251, being inconsistent with the prediction result, which needed to be further investigated. In the study of Buczkowicz et al. [2], the data was obtained from tumor tissue biopsy vs. normal. It is possible that different cell types contribute to gene expression change, therefore it is really a limitation that only one cell line was used for gene validation. We will continue collecting tissue samples for validation in the future.

In conclusion, this study indicated that GRM1, GRM7 and HTR2A might function in DIPG through the calcium signaling pathway and the neuroactive ligand–receptor interaction pathway. Meanwhile, TFAP2C and hsa-miR-26b-5p might have critical roles in the tumorigenesis of DIPG. This study provides new insights into the molecular mechanisms for the progress of DIPG and suggests directions for future study.

Highlights

  1. 1.

    A total of 378 differentially-expressed genes were identified.

     
  2. 2.

    We found 490 protein–protein interactions, 9 transcription factors and 27 microRNAs.

     
  3. 3.

    GRM1, HTR2A, TFAP2C and hsa-miR-26b-5p might be related to diffuse intrinsic pontine glioma.

     

Notes

Abbreviations

DIPG: 

diffuse intrinsic pontine glioma

DEGs: 

differentially-expressed genes

PPI: 

protein–protein interaction

TF: 

transcription factor

RAM: 

robust multi-array average

BP: 

biological process

MF: 

molecular function

CC: 

cellular component

Declarations

Authors’ contributions

FH carried out the conception and design of the research, participated in the acquisition of data and drafted the manuscript. WZ carried out the analysis and interpretation of data. BY participated in the Statistical analysis. WC participated in the design of the study and performed the statistical analysis. LW conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Not applicable. This study was only the primary research, and further study has been in progress.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This study was approved by Ethics Committee of Shanghai Jiao Tong University and Shanghai Sanda University.

Funding

None.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Rehabilitation, Shanghai General Hospital, Shanghai Jiao Tong University, No. 100, Haining Road, Shanghai, 200080, China
(2)
School of International Medical Technology, Shanghai Sanda University, No. 2727, Jinhai Road, Shanghai, 201209, China

References

  1. Vanan MI, Eisenstat DD. DIPG in children—what can we learn from the past? Front Oncol. 2015;5:237.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, Morrison A, Lewis P, Bouffet E, Bartels U, Zuccaro J, Agnihotri S, Ryall S, Barszczyk M, Chornenkyy Y, Bourgey M, Bourque G, Montpetit A, Cordero F, Castelo-Branco P, Mangerel J, Tabori U, Ho KC, Huang A, Taylor KR, Mackay A, Bendel AE, Nazarian J, Fangusaro JR, Karajannis MA, Zagzag D, Foreman NK, Donson A, Hegert JV, Smith A, Chan J, Lafay-Cousin L, Dunn S, Hukin J, Dunham C, Scheinemann K, Michaud J, Zelcer S, Ramsay D, Cain J, Brennan C, Souweidane MM, Jones C, Allis CD, Brudno M, Becher O, Hawkins C. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet. 2014;46(5):451–6.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Donaldson SS, Laningham F, Fisher PG. Advances toward an understanding of brainstem gliomas. J Clin Oncol. 2006;24(8):1266–72.View ArticlePubMedGoogle Scholar
  4. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol. 2006;7(3):241–8.View ArticlePubMedGoogle Scholar
  5. Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily MA, Quist MJ, Davis LE, Huang EC, Woo PJ, Ponnuswami A, Chen S, Johung TB, Sun W, Kogiso M, Du Y, Qi L, Huang Y, Hutt-Cabezas M, Warren KE, Le Dret L, Meltzer PS, Mao H, Quezado M, van Vuurden DG, Abraham J, Fouladi M, Svalina MN, Wang N, Hawkins C, Nazarian J, Alonso MM, Raabe EH, Hulleman E, Spellman PT, Li XN, Keller C, Pal R, Grill J, Monje M. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med. 2015;21(6):555–9.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Monje M, Mitra SS, Freret ME, Raveh TB, Kim J, Masek M, Attema JL, Li G, Haddix T, Edwards MS, Fisher PG, Weissman IL, Rowitch DH, Vogel H, Wong AJ, Beachy PA. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci USA. 2011;108(11):4453–8.View ArticlePubMedGoogle Scholar
  7. Hashizume R, Smirnov I, Liu S, Phillips JJ, Hyer J, McKnight TR, Wendland M, Prados M, Banerjee A, Nicolaides T, Mueller S, James CD, Gupta N. Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment. J Neurooncol. 2012;110(3):305–13.View ArticlePubMedGoogle Scholar
  8. Nakada M, Niska JA, Tran NL, McDonough WS, Berens ME. EphB2/R-Ras signaling regulates glioma cell adhesion, growth, and invasion. Am J Pathol. 2005;167(2):565–76.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 2000;25(1):55–7.View ArticlePubMedGoogle Scholar
  10. Deng L, Xiong P, Luo Y, Bu X, Qian S, Zhong W. Bioinformatics analysis of the molecular mechanism of diffuse intrinsic pontine glioma. Oncol Lett. 2016;12(4):2524–30.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Xi Y, Tang W, Yang S, Li M, He Y, Fu X. Mining the glioma susceptibility genes in children from gene expression profiles and a methylation database. Oncol Lett. 2017;14(3):3473–9.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Barrett T, Suzek TO, Troup DB, Wilhite SE, Ngau W-C, Ledoux P, Rudnev D, Lash AE, Fujibuchi W, Edgar R. NCBI GEO: mining millions of expression profiles—database and tools. Nucleic Acids Res. 2005;33(suppl 1):D562–6.PubMedGoogle Scholar
  13. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307–15.View ArticlePubMedGoogle Scholar
  14. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S, editors. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer; 2005. p. 397–420.View ArticleGoogle Scholar
  15. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene Ontology: tool for the unification of biology. Nat Genet. 2000;25(1):25–9.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28(1):27–30.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Du J, Yuan Z, Ma Z, Song J, Xie X, Chen Y. KEGG-PATH: Kyoto Encyclopedia of Genes and Genomes-based pathway analysis using a path analysis model. Mol BioSyst. 2014;10(9):2441–7.View ArticlePubMedGoogle Scholar
  18. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2008;4(1):44–57.View ArticleGoogle Scholar
  19. Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics. 2013;29:661–3.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman W-H, Pagès F, Trajanoski Z, Galon J. ClueGO: a Cytoscape plug-into decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091–3.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP. STRING v10: protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2014;43:D447–52.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Tang Y, Li M, Wang J, Pan Y, Wu F-X. CytoNCA: a Cytoscape plugin for centrality analysis and evaluation of protein interaction networks. BioSystems. 2015;127(Complete):67–72.View ArticlePubMedGoogle Scholar
  24. Bandettini WP, Kellman P, Mancini C, Booker OJ, Vasu S, Leung SW, Wilson JR, Shanbhag SM, Chen MY, Arai AE. MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 2012;14:83.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Slezakprochazka I, Durmus S, Kroesen BJ, Van den Berg A. MicroRNAs, macrocontrol: regulation of miRNA processing. RNA. 2010;16(6):1087–95.View ArticleGoogle Scholar
  26. Zaret KS, Carroll JS. Pioneer transcription factors: establishing competence for gene expression. Genes Dev. 2011;25(21):2227–41.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Delfino KR, Rodriguez-Zas SL. Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence. PLoS ONE. 2013;8(3):12.View ArticleGoogle Scholar
  28. Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015;12(8):697.View ArticlePubMedGoogle Scholar
  29. RS Janky, Verfaillie A, Imrichová H, Van de Sande B, Standaert L, Christiaens V, Hulselmans G, Herten K, Naval Sanchez M, Potier D, Svetlichnyy D, Kalender Atak Z, Fiers M, Marine J-C, Aerts S. iRegulon: from a gene list to a gene regulatory network using large motif and track collections. PLoS Comput Biol. 2014;10(7):e1003731.View ArticleGoogle Scholar
  30. Matys V, Fricke E, Geffers R, Gößling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV. TRANSFAC®: transcriptional regulation, from patterns to profiles. Nucleic Acids Res. 2003;31(1):374–8.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Matys V, Kelmargoulis OV, Fricke E, Liebich I, Land S, Barredirrie A, Reuter I, Chekmenev D, Krull M, Hornischer K. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 2006;34(suppl_1):D108–10.View ArticlePubMedGoogle Scholar
  32. Sloan CA, Chan ET, Davidson JM, Malladi VS, Strattan JS, Hitz BC, Gabdank I, Narayanan AK, Ho M, Lee BT. ENCODE data at the ENCODE portal. Nucleic Acids Res. 2016;44(d1):D726–32.View ArticlePubMedGoogle Scholar
  33. Xu D, Ma P, Gao G, Gui Y, Niu X, Jin B. MicroRNA-383 expression regulates proliferation, migration, invasion, and apoptosis in human glioma cells. Tumor Biol. 2015;36(10):7743–53.View ArticleGoogle Scholar
  34. Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, Sarkaria J, Zhang Z. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013;27(9):985–90.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Mariot P, Vanoverberghe K, Lalevee N, Rossier MF, Prevarskaya N. Overexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells. J Biol Chem. 2002;277(13):10824–33.View ArticlePubMedGoogle Scholar
  36. Stewart TA, Yapa KT, Monteith GR. Altered calcium signaling in cancer cells. Biochim Biophys Acta. 2015;1848(10 Pt B):2502.View ArticlePubMedGoogle Scholar
  37. Kalariti N, Pissimissis N, Koutsilieris M. The glutamatergic system outside the CNS and in cancer biology. Expert Opin Investig Drugs. 2005;14(12):1487–96.View ArticlePubMedGoogle Scholar
  38. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 1997;37:205–37.View ArticlePubMedGoogle Scholar
  39. Frati C, Marchese C, Fisichella G, Copani A, Nasca MR, Storto M, Nicoletti F. Expression of functional mGlu5 metabotropic glutamate receptors in human melanocytes. J Cell Physiol. 2000;183(3):364–72.View ArticlePubMedGoogle Scholar
  40. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D. Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol Sci. 2007;28(5):206–13.View ArticlePubMedGoogle Scholar
  41. Watanabe K, Kanno T, Oshima T, Miwa H, Tashiro C, Nishizaki T. The NMDA receptor NR2A subunit regulates proliferation of MKN45 human gastric cancer cells. Biochem Biophys Res Commun. 2008;367(2):487–90.View ArticlePubMedGoogle Scholar
  42. de Groot JF, Piao Y, Lu L, Fuller GN, Yung WK. Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol. 2008;88(2):121–33.View ArticlePubMedGoogle Scholar
  43. Zhu H, Reuhl K, Botha R, Ryan K, Wei J, Chen S. Development of early melanocytic lesions in transgenic mice predisposed to melanoma. Pigment Cell Res. 2000;13(3):158–64.View ArticlePubMedGoogle Scholar
  44. Zhu H, Reuhl K, Zhang X, Botha R, Ryan K, Wei J, Chen S. Development of heritable melanoma in transgenic mice. J Invest Dermatol. 1998;110(3):247–52.View ArticlePubMedGoogle Scholar
  45. Brocke KS, Staufner C, Luksch H, Geiger KD, Stepulak A, Marzahn J, Schackert G, Temme A, Ikonomidou C. Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther. 2010;9(6):455–68.View ArticlePubMedGoogle Scholar
  46. Li ML, Hu XQ, Li F, Gao WJ. Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: still promising or a dead end? Prog Neuropsychopharmacol Biol Psychiatry. 2015;60:66–76.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Ma K, Cheng Z, Sun L, Li H. Identification of potential therapeutic targets for gliomas by bioinformatics analysis. Oncol Lett. 2017;14(5):5203–10.PubMedPubMed CentralGoogle Scholar
  48. Jeong H, Mason S, Barabasi A, Oltvai ZN. Lethality and centrality in protein networks. Nature. 2001;411(6833):41–2.View ArticlePubMedGoogle Scholar
  49. de Sousa RT, Loch AA, Carvalho AF, Brunoni AR, Haddad MR, Henter ID, Zarate CA, Machado-Vieira R. Genetic studies on the tripartite glutamate synapse in the pathophysiology and therapeutics of mood disorders. Neuropsychopharmacology. 2016;42:787.View ArticlePubMedPubMed CentralGoogle Scholar
  50. Tryndyak V, Kovalchuk O, Pogribny IP. Identification of differentially methylated sites within unmethylated DNA domains in normal and cancer cells. Anal Biochem. 2006;356(2):202–7.View ArticlePubMedGoogle Scholar
  51. Li Y, Wang D, Wang L, Yu J, Du D, Chen Y, Gao P, Wang DM, Zhang F, Fu S. Distinct genomic aberrations between low-grade and high-grade gliomas of Chinese patients. PLoS ONE. 2013;8(2):22.Google Scholar
  52. Hall S, Hunt M, Simon A, Cunnington LG, Carracedo LM, Schofield IS, Forsyth R, Traub RD, Whittington MA. Unbalanced peptidergic inhibition in superficial neocortex underlies spike and wave seizure activity. J Neurosci. 2015;35(25):9302–14.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Shi L, Zhang J, Pan T, Zhou J, Gong W, Liu N, Fu Z, You Y. MiR-125b is critical for the suppression of human U251 glioma stem cell proliferation. Brain Res. 2010;1312:120–6.View ArticlePubMedGoogle Scholar
  54. Liu C, Yao J, Mercola D, Adamson E. The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem. 2000;275(27):20315–23.View ArticlePubMedGoogle Scholar
  55. Zhang Y, Chao T, Li R, Liu W, Chen Y, Yan X, Gong Y, Yin B, Qiang B. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. J Mol Med. 2009;87(1):43.View ArticlePubMedGoogle Scholar
  56. Kim W, Kim E, Lee S, Kim D, Chun J, Park KH, Youn H, Youn B. TFAP2C-mediated upregulation of TGFBR1 promotes lung tumorigenesis and epithelial–mesenchymal transition. Exp Mol Med. 2016;48(11):e273.View ArticlePubMedPubMed CentralGoogle Scholar
  57. De Andrade JP, Park JM, Gu VW, Woodfield GW, Kulak MV, Lorenzen AW, Wu VT, Van Dorin SE, Spanheimer PM, Weigel RJ. EGFR is regulated by TFAP2C in luminal breast cancer and is a target for vandetanib. Mol Cancer Ther. 2016;15:503–11.View ArticlePubMedPubMed CentralGoogle Scholar
  58. Wu T, Chen W, Liu S, Lu H, Wang H, Kong D, Huang X, Kong Q, Ning Y, Lu Z. Huaier suppresses proliferation and induces apoptosis in human pulmonary cancer cells via upregulation of miR-26b-5p. FEBS Lett. 2014;588(12):2107–14.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s) 2018

Advertisement

Biological Research

ISSN: 0717-6287

Contact us